Hot And Hotter: Lepu Takes $140m Leap Into China Immuno-Oncology Fray
Established just a year ago, China's Lepu Biotech has raised a mighty $131m to develop immuno-oncology antibodies, while Shanghai-based Asieris has obtained worldwide rights to develop and commercialize Photocure's Cevira for cervical dysplasia.
You may also be interested in...
Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.
Emerging Company Profile: Aiming to change the current practice of surgically removing the bladder, China Asieris hopes to use an older drug to treat early-onset bladder cancer. This is the fourth and last in a series of China-based Emerging Company Profiles.
Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.